Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDX RA

Drug Profile

MDX RA

Alternative Names: 4197X-RA; Monoclonal antibody ricin A

Latest Information Update: 20 Feb 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Houston Biotechnology
  • Class Drug conjugates; Eye disorder therapies; Immunotoxins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cataracts

Most Recent Events

  • 18 May 2004 Suspended - Preclinical for Cataracts in Japan (unspecified route)
  • 31 Jan 2002 The collaboration between Scil Biomedicals and Medarex has ended
  • 31 Oct 2000 IDM has acquired certain economic interests in MDX RA as part of an expansion of its partnership with Medarex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top